- Home
- SIGA vs TERN Comparison
SIGA vs TERN Comparison
Compare SIGA & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIGA
- TERN
- Stock Information
- Founded
- SIGA 1995
- TERN 2017
- Country
- SIGA United States
- TERN United States
- Employees
- SIGA N/A
- TERN N/A
- Industry
- SIGA Biotechnology: Pharmaceutical Preparations
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- SIGA Health Care
- TERN Health Care
- Exchange
- SIGA Nasdaq
- TERN Nasdaq
- Market Cap
- SIGA 594.3M
- TERN 710.6M
- IPO Year
- SIGA 1997
- TERN 2021
- Fundamental
- Price
- SIGA $8.06
- TERN $7.90
- Analyst Decision
- SIGA
- TERN Buy
- Analyst Count
- SIGA 0
- TERN 7
- Target Price
- SIGA N/A
- TERN $13.99
- AVG Volume (30 Days)
- SIGA 349.5K
- TERN 1.7M
- Earning Date
- SIGA 11-10-2025
- TERN 11-12-2025
- Dividend Yield
- SIGA 7.38%
- TERN N/A
- EPS Growth
- SIGA N/A
- TERN N/A
- EPS
- SIGA 1.14
- TERN N/A
- Revenue
- SIGA $179,639,422.00
- TERN N/A
- Revenue This Year
- SIGA N/A
- TERN N/A
- Revenue Next Year
- SIGA $115.06
- TERN N/A
- P/E Ratio
- SIGA $7.14
- TERN N/A
- Revenue Growth
- SIGA 3.86
- TERN N/A
- 52 Week Low
- SIGA $4.95
- TERN $1.87
- 52 Week High
- SIGA $9.62
- TERN $9.03
- Technical
- Relative Strength Index (RSI)
- SIGA 40.69
- TERN 49.14
- Support Level
- SIGA $8.07
- TERN $7.12
- Resistance Level
- SIGA $8.54
- TERN $8.87
- Average True Range (ATR)
- SIGA 0.24
- TERN 0.63
- MACD
- SIGA -0.03
- TERN -0.08
- Stochastic Oscillator
- SIGA 11.01
- TERN 44.71
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.